iPubs - Lundbeck - Custom Email #2

To: [HCP email]
From: NeurologyLive <news@neurologylive.com>
Subject: The Science of VYEPTI^™ (eptinezumab-jjmr)

No Images? Click here

For more information, please see the Prescribing Information and Patient Information.

The Science of Monoclonal Antibodies and the Emergence of VYEPTI^™ (eptinezumab-jjmr) for the Preventive Treatment
of Migraine

View iPub^®

This iPub^® is sponsored by Lundbeck and is not
approved for Continuing Medical Education.

Join our expert faculty to learn more about VYEPTI for the preventive treatment of migraine in adults. VYEPTI is the first and only intravenous calcitonin gene-related peptide antagonist (IV anti-CGRP) specifically designed to deliver fast, powerful, and sustained migraine prevention.^1,2

Faculty information

Jessica Ailani, MD, FAHS, FAAN

Professor of Clinical Neurology
Director, Georgetown Headache Center
MedStar Georgetown University Hospital
Washington, DC

Andrew Charles, MD

Professor of Neurology
Meyer and Renee Luskin Chair
in Migraine and Headache Studies
Director, Goldberg Migraine Program
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA

In this iPub^®, Drs. Jessica Ailani and Andrew Charles will:

Review migraine pathophysiology, the role of CGRP, and the rationale for CGRP as a therapeutic target in migraine prevention

Provide perspectives on the science behind therapeutic monoclonal antibodies, with a focus on specific design elements

Evaluate the pharmacokinetics and potential mechanism of action of eptinezumab-jjmr

Explore the efficacy and safety profile of VYEPTI^™ (eptinezumab-jjmr) and examine considerations for appropriate patients

View iPub^®

Indication

VYEPTI is indicated for the preventive treatment of migraine in adults.

Important Safety Information

CONTRAINDICATIONS

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

WARNINGS AND PRECAUTIONS

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

ADVERSE REACTIONS

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information
and Patient Information.

References:

1. VYEPTI [package insert]. Deerfield, IL: Lundbeck Seattle BioPharmaceuticals, Inc.
2. Data on file. Deerfield, IL: Lundbeck Seattle BioPharmaceuticals, Inc.

Forward